Peptide evidence comparisons
When two peptides are discussed together in research and online, we publish a structured side-by-side comparison: mechanism, human-data status, regulatory context, safety uncertainty, mechanistic overlap and translational limits. These pages are evidence comparisons, not “which is better” product comparisons.
For per-peptide evidence summaries see peptide monographs. For grading methodology see evidence grading A–X.
BPC-157 vs TB-500
BPC-157 vs TB-500 — Healing Peptide Comparison
Head-to-head research comparison of BPC-157 and TB-500, the two most-studied tissue-repair peptides, covering mechanism, dosing, and stack utility.
Last reviewed: 2026-08-28
CJC-1295 (no DAC) vs Tesamorelin
CJC-1295 vs Tesamorelin — Comparing Two GHRH Analogues
Head-to-head comparison of CJC-1295 (no DAC) and Tesamorelin: mechanism, half-life, dosing schedule, evidence base, and which research context suits each GHRH analogue.
Last reviewed: 2026-08-28
Epitalon vs Thymalin
Epitalon vs Thymalin — Pineal vs Thymic Bioregulator Comparison
Head-to-head research comparison of Epitalon and Thymalin, Khavinson's pineal and thymic bioregulators, covering telomere biology, immune senescence, and the canonical combined protocol.
Last reviewed: 2026-08-28
Ipamorelin vs GHRP-2
Ipamorelin vs GHRP-2 — Comparing Selective and First-Generation GHRPs
Ipamorelin vs GHRP-2: mechanism, selectivity, cortisol impact, dosing, and which GHRP suits your GH-axis research protocol in 2026.
Last reviewed: 2026-08-28
MK-677 vs GHRP-2
MK-677 vs GHRP-2 — Non-Peptide Oral vs Peptide Injectable Ghrelin-Receptor Agonists
MK-677 (ibutamoren, oral non-peptide) vs GHRP-2 (pralmorelin, injectable peptide): shared receptor target, different chemistry, different regulatory status. UK research-literacy comparison.
Last reviewed: 2026-08-28
MOTS-c vs AOD-9604
MOTS-c vs AOD-9604 — Mitochondrial vs GH-Fragment Fat-Loss Comparison
Research comparison of MOTS-c and AOD-9604: mechanisms, dosing, and evidence for fat-loss and metabolic research protocols.
Last reviewed: 2026-08-28
MOTS-c vs Humanin
MOTS-c vs Humanin — Two Mitochondrial-Derived Peptides Compared
MOTS-c and humanin are mitochondrial-derived peptides encoded within human mitochondrial DNA, but they act on different receptors, tissues, and endpoints.
Last reviewed: 2026-08-28
Semax vs Selank
Semax vs Selank — Russian Nootropic Heptapeptide Comparison
Semax vs Selank: mechanism-by-mechanism comparison of two Russian heptapeptides — BDNF/cognitive axis vs GABAergic anxiolytic axis. Dosing, evidence, and sourcing.
Last reviewed: 2026-08-28
SS-31 vs MOTS-c
SS-31 vs MOTS-c — Mitochondria-Targeted Synthetic vs Endogenous MDP
SS-31 (elamipretide) is a synthetic cardiolipin-stabilising peptide; MOTS-c is an endogenous mitochondrial-derived peptide. Same organelle, different origins, different mechanisms.
Last reviewed: 2026-08-28
Tirzepatide vs Cagrilintide
Tirzepatide vs Cagrilintide — Incretin vs Amylin Approach to Weight Reduction
Tirzepatide (dual GIP/GLP-1 agonist, MHRA-licensed) vs Cagrilintide (long-acting amylin analogue, investigational): mechanisms, evidence base, and UK regulatory framing.
Last reviewed: 2026-08-28
Tirzepatide vs Retatrutide
Tirzepatide vs Retatrutide — Dual vs Triple Incretin Agonist Comparison
Tirzepatide vs Retatrutide: dual vs triple incretin agonist mechanisms, Phase II/III efficacy data, dosing, tolerability, and UK research status compared.
Last reviewed: 2026-08-28
Tirzepatide vs Semaglutide
Tirzepatide vs Semaglutide — Dual vs Mono Incretin Agonist Comparison
Tirzepatide vs Semaglutide (Mounjaro vs Ozempic/Wegovy): mechanisms, SURMOUNT-1 vs STEP-1 efficacy data, SURPASS-2 head-to-head results, dosing, and UK research status.
Last reviewed: 2026-08-28